Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

Leonardi, 2003, Etanercept as monotherapy in patients with psoriasis, N Engl J Med, 349, 2014, 10.1056/NEJMoa030409 Papp, 2005, A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction, Br J Dermatol, 152, 1304, 10.1111/j.1365-2133.2005.06688.x Reich, 2005, Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial, Lancet, 366, 1367, 10.1016/S0140-6736(05)67566-6 Menter, 2007, A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis, J Am Acad Dermatol, 56, 31.e1, 10.1016/j.jaad.2006.07.017 Menter, 2008, Adalimumab therapy for moderate-to-severe psoriasis: a randomized, controlled phase III trial, J Am Acad Dermatol, 58, 106, 10.1016/j.jaad.2007.09.010 Saurat, 2008, Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION), Br J Dermatol, 158, 558, 10.1111/j.1365-2133.2007.08315.x Papp, 2008, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2), Lancet, 371, 1675, 10.1016/S0140-6736(08)60726-6 Leonardi, 2008, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX I), Lancet, 371, 1665, 10.1016/S0140-6736(08)60725-4 European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf. Accessed on January 20, 2015. Ryan, 2014, Research gaps in psoriasis: opportunities for future studies, J Am Acad Dermatol, 70, 146, 10.1016/j.jaad.2013.08.042 Revicki, 2008, Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis, Dermatology, 216, 260, 10.1159/000113150 Mattei, 2014, Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies, J Eur Acad Dermatol Venereol, 28, 333, 10.1111/jdv.12106 Puig, 2015, PASI90 response: the new standard in therapeutic efficacy for psoriasis, J Eur Acad Dermatol Venereol, 29, 645, 10.1111/jdv.12817 Hueber, 2010, Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis, Sci Transl Med, 2, 52ra72, 10.1126/scitranslmed.3001107 Nestle, 2009, Psoriasis, N Engl J Med, 361, 496, 10.1056/NEJMra0804595 Kim, 2015, The immunopathogenesis of psoriasis, Dermatol Clin, 33, 13, 10.1016/j.det.2014.09.002 Zaba, 2007, Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses, J Exp Med, 204, 3183, 10.1084/jem.20071094 Langley, 2014, Secukinumab in plaque psoriasis–results of two phase 3 trials, N Engl J Med, 371, 326, 10.1056/NEJMoa1314258 Paul, 2015, Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE), J Eur Acad Dermatol Venereol, 29, 1082, 10.1111/jdv.12751 Blauvelt, 2015, Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE), Br J Dermatol, 172, 484, 10.1111/bjd.13348 European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). Summary of opinion on secukinumab. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003729/WC500177620.pdf. Accessed on January 20, 2015. 2015 Griffiths, 2010, Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis, N Engl J Med, 362, 118, 10.1056/NEJMoa0810652 2014 Langley, 2015, The 5-point investigator's global assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials, J Dermatolog Treat, 26, 23, 10.3109/09546634.2013.865009 Finlay, 1994, Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use, Clin Exp Dermatol, 19, 210, 10.1111/j.1365-2230.1994.tb01167.x Bretz, 2009, A graphical approach to sequentially rejective multiple test procedures, Stat Med, 28, 586, 10.1002/sim.3495 Papp, 2013, Long-term safety of ustekinumab in patients with moderate to severe psoriasis: final results from 5 years of follow-up, Br J Dermatol, 168, 844, 10.1111/bjd.12214